Pharmacogenomics of microRNA: A miRSNP towards individualized therapy

Pharmacogenomics

Volumn 8, Issue 12, 2007, Pages 1625-1627

  Bertino, Joseph R ^a   Banerjee, Debabrata ^a   Mishra, Prasun J ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FLUOROURACIL; METHOTREXATE; MICRORNA; MICRORNA 24; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ALPHA THALASSEMIA; BINDING SITE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; COMBINATION CHEMOTHERAPY; CONDYLOMA; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; HUMAN GENOME; INSULIN SENSITIVITY; MONOTHERAPY; PHARMACOGENOMICS; PROTEIN EXPRESSION; RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; UROLITHIASIS;

3' UNTRANSLATED REGIONS; DRUG RESISTANCE; HUMANS; METHOTREXATE; MICRORNAS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 37749027621     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.12.1625     Document Type: Editorial

References (19)

1. Mishra PJ, Humeniuk R Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR: A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA 104(33), 13513-13518 (2007).
2. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993).
3. Berezikov E, Guryev V, van de Belt J, Wienholds L, Piasterk RH, Cuppen E: Phylogene is shadowing and computational identification of human microRNA genes. Cell 120(1), 21-24 (2005).
4. Xie X, Lu J, Kulbokas EJ: Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434, 338-345 (2005).
5. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1), 15-20. (2005).
6. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
7. Lesko LJ, Woodcock J: Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug Discov. 3(9), 763-769 (2004).
8. Davies SM: Pharmacogenetics, pharmacogenomics and personalized medicine: are we there yet? Hematology Am. Soc. Hematol. Educ. Program 111-117 (2006).
9. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature 429, 464-468 (2004).
10. Bailey DS, Bondar A, Furness LM: Pharmacogenomics - it's not just pharmacogenetics. Curr. Opin. Biotechnol. 9(6), 595-601 (1998).
11. Cheok MH, Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 6(2), 117-129 (2006).
12. Lindpaintner K: The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat. Rev. Drug Discov. 1(6), 463-469. (2002).
13. Calin GA, Liu CG, Sevignani C et al.: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101(32), 11755-11760 (2004).
14. Calin GA, Dumitru CD, Shimizu M et al.: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002).
15. Alt FW, Kellems RE, Bertino JR, Schimke RT: Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J. Biol. Chem. 253(5), 1357-1370 (1978).
16. Mazumder B, Seshadri V, Fox PL: Translational control by the 3′-UTR: the ends specify the means. Trends Biochem. Sci. 28(2), 91-98 (2003).
17. Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF: Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum. Genet. 51(3), 155-160 (2006).
18. Standart N, Jackson RJ: MicroRNAs repress translation of m7Gppp-capped target mRNAs in vitro by inhibiting initiation and promoting deadenylation. Genes Dev. 21(16), 1975-1982 (2007).
19. Jing Q, Huang R, Guth S et al.: Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120(5), 623-634 (2005).